Tests darovasertib before surgery or radiation for uveal melanoma
Tests darovasertib given before primary local therapy in adults with uveal melanoma.
Plain-language title generated from the registry record
Registry title: Neoadjuvant Darovasertib in Primary Uveal Melanoma
Key facts
- Where
- L'hospitalet De Llobregat, Pamplona, Santiago de Compostela, Sevilla, and Valladolid, SpainSee the 5 sites
- Phase
- Phase 3
Where in Spain
- Bellvitge University HospitalL'hospitalet De Llobregat, SpainTaking people
- Clínica Universidad de navarraPamplona, SpainTaking people
- Hospital Provincial de ConxoSantiago de Compostela, SpainTaking people
- Hospital Universitario Virgen De La MacarenaSevilla, SpainTaking people
- Hospital Clínico Universitario de ValladolidValladolid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IDEAYA Biosciences
- Trial code
- NCT07015190EU 2025-522387-32-00
- Record updated
- 6 May 2026
- Original description
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)Read full original descriptionShow less
A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Inclusion: Primary non-metastatic uveal melanoma; Able and willing to provide written, informed consent before initiation of any study-related procedures, and in the opinion of the Investigator, to comply with all study requirements; ECOG 0 or 1; Adequate organ function.
Exclusion: Previous treatment for UM; Attributes that necessitate enucleation regardless of response to therapy; Evidence of progressive secondary underlying ocular disease that would confound longitudinal VA assessments; Presence of a malignant disease other than the one being treated in this study; Evidence of metastatic UM.